Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05347095
Registration number
NCT05347095
Ethics application status
Date submitted
21/04/2022
Date registered
26/04/2022
Date last updated
22/05/2024
Titles & IDs
Public title
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Query!
Scientific title
A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Query!
Secondary ID [1]
0
0
2021-000491-10
Query!
Secondary ID [2]
0
0
CR109189
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FUZION CD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fistulizing Crohns Disease
0
0
Query!
Perianal Crohns Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab
Treatment: Drugs - Placebo
Experimental: Group 1: Guselkumab - Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.
Experimental: Group 2: Guselkumab - Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
Experimental: Group 3: Placebo - Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
Treatment: Drugs: Guselkumab
Guselkumab will be administered subcutaneously/IV infusion.
Treatment: Drugs: Placebo
Matching placebo will be administered subcutaneously/IV infusion.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants who Achieve Combined Fistula Remission at Week 24
Query!
Assessment method [1]
0
0
Percentage of participants who achieve combined fistula remission at Week 24 will be reported. Combined fistula remission is defined as 100 percentage (%) closure of all treated external openings without development of new fistulas or abscesses and without any drainage by the external openings [occurring spontaneously or after gentle finger compression] and absence of collections greater than (>) 2 centimeters (cm) of the perianal fistulas in at least two of three dimensions, confirmed by a blinded central review of the magnetic resonance imaging [MRI] results.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Percentage of Participants who Achieve Combined Fistula Remission at Week 48
Query!
Assessment method [1]
0
0
Percentage of participants who achieve combined fistula remission at Week 48 will be reported.
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [2]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Remission
Query!
Assessment method [2]
0
0
Percentage of participants who achieve clinically assessed fistula remission will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [3]
0
0
Percentage of Participants who Achieve Radiological Fistula Remission Based on Radiological Findings Assessed by MRI
Query!
Assessment method [3]
0
0
Percentage of participants who achieve radiological fistula remission based on radiological findings assessed by MRI will be reported. Radiological remission is defined as absence of collections >2 cm of the perianal fistulas in at least two of three dimensions, confirmed by a blinded central review of the MRI results.
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Response at Week 24
Query!
Assessment method [4]
0
0
Percentage of participants who achieve clinically assessed fistula response at Week 24 will be reported. Clinically assessed fistula response is defined as closure of at least 50 percent (%) of all external openings that were draining at baseline.
Query!
Timepoint [4]
0
0
Week 24
Query!
Secondary outcome [5]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Response at Week 12
Query!
Assessment method [5]
0
0
Percentage of participants who achieve clinically assessed fistula response at Week 12 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.
Query!
Timepoint [5]
0
0
Week 12
Query!
Secondary outcome [6]
0
0
Change from Baseline in Crohn's Disease Activity Index (CDAI) by Visit Over Time Through Week 48
Query!
Assessment method [6]
0
0
Change from baseline in CDAI by visit over time will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being with scores ranging from 0 to approximately 600. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on a daily basis.
Query!
Timepoint [6]
0
0
Baseline up to Week 48
Query!
Secondary outcome [7]
0
0
Percentage of Participants who Achieve Clinical Remission (CDAI less than [<] 150) by Visit Over Time Through Week 48 Among Participants with CDAI Greater than (>) 150 at Baseline
Query!
Assessment method [7]
0
0
Percentage of participants who achieve clinical remission (CDAI <150) by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain [AP]/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being with scores ranging from 0 to approximately 600. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on a daily basis.
Query!
Timepoint [7]
0
0
Through Week 48
Query!
Secondary outcome [8]
0
0
Percentage of Participants who Achieve a Clinical Response by Visit Over Time Through Week 48 Among Participants with CDAI >150 at Baseline
Query!
Assessment method [8]
0
0
Percentage of participants who achieve a clinical response by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. Clinical response is defined greater than or equal to (>=) 100-point reduction from baseline in CDAI, or CDAI <150.
Query!
Timepoint [8]
0
0
Through Week 48
Query!
Secondary outcome [9]
0
0
Percentage of Participants who Achieve Steroid-free Clinical Remission by Visit Over Time Through Week 48 Among Participants with CDAI >150 at Baseline
Query!
Assessment method [9]
0
0
Percentage of participants who achieve steroid-free clinical remission by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. Steroid-free clinical remission is defined as CDAI <150 and not receiving corticosteroids by visit over time through Week 48 among participants with CDAI >150 at baseline.
Query!
Timepoint [9]
0
0
Through Week 48
Query!
Secondary outcome [10]
0
0
Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Response Among Participants With CDAI >220 at Baseline
Query!
Assessment method [10]
0
0
Percentage of participants who achieve combined clinical response and clinically assessed fistula response among participants with CDAI >220 at baseline at baseline will be reported. Clinical response is defined >=100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.
Query!
Timepoint [10]
0
0
Week 24 and Week 48
Query!
Secondary outcome [11]
0
0
Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Remission Among Participants with CDAI >220 at Baseline
Query!
Assessment method [11]
0
0
Percentage of participants who achieve combined clinical remission and clinically assessed fistula remission among participants with CDAI >220 at baseline at will be reported. Clinical remission is defined as CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [11]
0
0
Week 24 and Week 48
Query!
Secondary outcome [12]
0
0
Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Remission Among Participants with CDAI >220 at Baseline
Query!
Assessment method [12]
0
0
Percentage of participants who achieve combined clinical response and clinically assessed fistula remission among participants with CDAI >220 at baseline will be reported. Clinical response is defined >=100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [12]
0
0
Week 24 and Week 48
Query!
Secondary outcome [13]
0
0
Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Response among Participants with CDAI >220 at Baseline
Query!
Assessment method [13]
0
0
Percentage of participants who achieve combined clinical remission and clinically assessed fistula response among participants with CDAI >220 at baseline will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.
Query!
Timepoint [13]
0
0
Week 24 and Week 48
Query!
Secondary outcome [14]
0
0
Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Response at Week 24 and Week 48
Query!
Assessment method [14]
0
0
Percentage of participants who achieve combined clinical response and clinically assessed fistula response at Week 24 and Week 48 will be reported. Clinical response is defined >=100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.
Query!
Timepoint [14]
0
0
Week 24 and Week 48
Query!
Secondary outcome [15]
0
0
Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Remission at Week 24 and Week 48
Query!
Assessment method [15]
0
0
Percentage of participants who achieve combined clinical response and clinically assessed fistula remission at Week 24 and Week 48 will be reported. Clinical response is defined >=100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [15]
0
0
Week 24 and Week 48
Query!
Secondary outcome [16]
0
0
Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Response at Week 24 and Week 48
Query!
Assessment method [16]
0
0
Percentage of participants who achieve combined clinical remission and clinically assessed fistula response at Week 24 and Week 48 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.
Query!
Timepoint [16]
0
0
Week 24 and Week 48
Query!
Secondary outcome [17]
0
0
Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Remission at Week 24 and Week 48
Query!
Assessment method [17]
0
0
Percentage of participants who achieve combined clinical remission and clinically assessed fistula remission will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [17]
0
0
Week 24 and Week 48
Query!
Secondary outcome [18]
0
0
Change from Baseline in Perianal Disease Activity Index (PDAI) Overall Score, Discharge Score, and Pain Score by Visit Over Time Through Week 48
Query!
Assessment method [18]
0
0
Change from baseline in PDAI overall score, discharge score, and pain score by visit over time through Week 48 will be reported. The PDAI is a scoring system to evaluate the severity of perianal lesion associated with Crohn's disease. It includes the following 5 items: (a) Discharge; (0=no discharge to 4= Gross fecal soiling) (b) Pain; (0=no activity to 4= severe pain, severe limitation) (c) Restriction of sexual activity;(0=no perianal disease/skin tags to 4= unable to engage in sexual activity) (d) Type of perianal disease; (0=no perianal disease/skin tags to 4=Anal sphincter ulceration or fistulae with significant undermining ok skin) and (e) Degree of induration; (0=no induration to 4=gross fluctuance/abscess. Higher scores indicate more severe or active disease.
Query!
Timepoint [18]
0
0
Baseline up to Week 48
Query!
Secondary outcome [19]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Response by Visit Over Time Through Week 48
Query!
Assessment method [19]
0
0
Percentage of participants with clinically assessed fistula response by visit over time through Week 48 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.
Query!
Timepoint [19]
0
0
Through Week 48
Query!
Secondary outcome [20]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Remission by Visit over Time Through Week 48
Query!
Assessment method [20]
0
0
Percentage of participants with clinically assessed fistula remission by visit over through Week 48 time will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [20]
0
0
Through Week 48
Query!
Secondary outcome [21]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Remission at Week 48 Among the Participants who Achieve Clinical Fistula Remission at Week 24
Query!
Assessment method [21]
0
0
Percentage of participants who achieve clinically assessed fistula remission at Week 48 among the participants who achieve clinical fistula remission at Week 24 will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [21]
0
0
Week 48
Query!
Secondary outcome [22]
0
0
Percentage of Participants who Achieve Clinically Assessed Fistula Remission at Week 48 Among Those who Achieve Fistula Remission or Response at Week 24
Query!
Assessment method [22]
0
0
Percentage of participants achieving clinically assessed fistula remission at Week 48 among those who achieve fistula remission or response (defined either by clinical or radiological assessment) at Week 24 will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.
Query!
Timepoint [22]
0
0
Week 48
Query!
Secondary outcome [23]
0
0
Time to Clinical Fistula Remission
Query!
Assessment method [23]
0
0
Time to clinical fistula remission will be reported. Clinical fistula remission is defined as 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by the external openings (occurring spontaneously or after gentle finger compression).
Query!
Timepoint [23]
0
0
Up to Week 96
Query!
Secondary outcome [24]
0
0
Percentage of Participants who Achieve Radiological Fistula Predominantly Fibrotic Status for all Existent Fistulas Assessed by MRI at Week 24 and Week 48
Query!
Assessment method [24]
0
0
Percentage of participants who achieve radiological fistula predominantly fibrotic status for all existent fistulas assessed by MRI at Week 24 and Week 48 will be reported.
Query!
Timepoint [24]
0
0
Week 24 and Week 48
Query!
Secondary outcome [25]
0
0
Percentage of participants who Achieve Radiological Remission Based on Radiological Findings Assessed by MRI at Week 48
Query!
Assessment method [25]
0
0
Percentage of participants with radiological remission based on radiological findings assessed by MRI at Week 48 will be reported. Radiological remission is defined as absence of collections >2 cm of the perianal fistulas, confirmed by a blinded central review of the MRI results.
Query!
Timepoint [25]
0
0
Week 48
Query!
Secondary outcome [26]
0
0
Percentage of Participants who Achieve Radiological Remission Assessed by MRI at Week 48 Among the Participants who Achieve Radiological Remission at Week 24
Query!
Assessment method [26]
0
0
Percentage of participants who achieve radiological remission assessed by MRI at Week 48 among the participants who achieve radiological remission at Week 24 will be reported. Radiological remission is defined as absence of collections >2 cm of the perianal fistulas, confirmed by a blinded central review of the MRI results.
Query!
Timepoint [26]
0
0
Week 48
Query!
Secondary outcome [27]
0
0
Percentage of Participants who Achieve Combined Clinically Assessed and Radiological Fistula Remission at Week 48 Among the Participants who Achieve Combined Clinical and Radiological Fistula Remission at Week 24
Query!
Assessment method [27]
0
0
Percentage of participants who achieve combined clinically assessed and radiological (assessed by MRI) fistula remission at Week 48 among the participants who achieve combined clinical and radiological fistula remission at Week 24.
Query!
Timepoint [27]
0
0
Week 48
Query!
Secondary outcome [28]
0
0
Percentage of Participants who Achieve Combined Clinically Assessed and Radiological Fistula Remission as Week 48 Among the Participants with Clinical Fistula Response at Week 24
Query!
Assessment method [28]
0
0
Percentage of participants who achieve combined clinically assessed and radiological (assessed by MRI) fistula remission at Week 48 among the participants who achieve clinical fistula response at Week 24 will be reported.
Query!
Timepoint [28]
0
0
Week 48
Query!
Secondary outcome [29]
0
0
Percentage of Participants with Proctitis at Week 48 Among Participants with MRI-confirmed Proctitis at Baseline
Query!
Assessment method [29]
0
0
Percentage of participants with proctitis at Week 48 among participants with MRI-confirmed proctitis at baseline will be reported. Proctitis is defined as the inflammation of the lining of the rectum.
Query!
Timepoint [29]
0
0
Week 48
Query!
Secondary outcome [30]
0
0
Change from Baseline in Magnetic Resonance Novel Index for Fistula imaging in Crohn's disease (MAGNIFI-CD) by Visit Over Time Through Week 48
Query!
Assessment method [30]
0
0
Change from baseline in MAGNIFI-CD by visit over time through Week 48 will be reported. The MAGNIFI-CD is based on MRI assessment of 6 items including number of fistula tracts, fistula length, hyperintensity of primary tract on post-contrast T1-weighted images, dominant feature, extension, and inflammatory mass. The total MAGNIFI-CD score ranges from 0 (no disease activity) to 25 (severe disease activity). It assesses the MRI data and determines perianal fistulizing CD activity with improved operating characteristics compared to the Van Assche Index (VAI) and the modified VAI (mVAI).
Query!
Timepoint [30]
0
0
Baseline up to Week 48
Query!
Secondary outcome [31]
0
0
Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) by Visit Over Time Through Week 48
Query!
Assessment method [31]
0
0
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) by visit over time through Week 48 will be reported. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD to evaluate patient reported outcomes (PROs) across 4 dimensions: bowel symptoms (loose stools, AP), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Query!
Timepoint [31]
0
0
Baseline up to Week 48
Query!
Secondary outcome [32]
0
0
Change From Baseline in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score by Visit Over Time Through Week 48
Query!
Assessment method [32]
0
0
Change From baseline in FACIT-F Score at Week 48 will be reported. The FACIT-F is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists of 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score is calculated as the sum of the 13 item scores (reserved scores [4 - score]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Query!
Timepoint [32]
0
0
Baseline; Up to Week 48
Query!
Secondary outcome [33]
0
0
Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Crohn's Disease (WPAI:CD) by Visit Over Time Through Week 48
Query!
Assessment method [33]
0
0
Change from baseline in WPAI:CD by visit over time through Week 48 will be reported. The WPAI:CD assesses the impact of CD on work and activity during the past 7 days. The specificity of WPAI:CD is achieved by replacing "health problems" in the general health version of the WPAI with "CD." It consists of 6 questions, which elicit the following information: employment status; hours missed due to CD; hours missed due to other reasons; hours actually worked; the degree to which CD affected productivity while working from 0 (no effect) to 10 (maximum impairment); and the degree to which CD affected regular activities (from 0-10). The sum of worktime missed and impairment at work yields the overall work impairment (productivity loss) score; scores are expressed as percent of impairment/productivity loss, with higher scores indicating greater impairment.
Query!
Timepoint [33]
0
0
Baseline; Up to Week 48
Query!
Secondary outcome [34]
0
0
Change from Baseline in Quality-of-life as Assessed by European Quality-of-Life Five Dimension Five Level Scale (EQ5D-5L) Score by Visit Over Time Through Week 48
Query!
Assessment method [34]
0
0
Change from baseline in quality-of-life (EQ5D-5L) score by visit over time through Week 48 will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Query!
Timepoint [34]
0
0
Baseline up to Week 48
Query!
Secondary outcome [35]
0
0
Change from Baseline in the Jorge-Wexner Score by Visit Over Time Through Week 48
Query!
Assessment method [35]
0
0
Change from baseline in the Jorge-Wexner score by visit over time through Week 48 will be reported. The Jorge-Wexner scoring system cross-tabulates frequencies and different anal incontinence presentations.
Query!
Timepoint [35]
0
0
Baseline; Through Week 48
Query!
Secondary outcome [36]
0
0
Change from Baseline in the Inflammatory Bowel Disease-Disability Index (IBD-DI) by Visit Over Time Through Week 48
Query!
Assessment method [36]
0
0
Change from baseline in the Inflammatory Bowel Disease-Disability Index (IBD-DI) by visit over time through Week 48 will be reported. The IBD-DI consists of 28 items that evaluate the 5 domains of overall health, body function, body structures, activity participation and environmental factors. Each item response is graded from 0 to 4 for each area evaluated (0 = very good; 1 = Good; 2 = medium; 3 = Bad; 4 = Very bad). The final composite score representative of the overall degree of disability ranging from -80 (maximum degree of disability) to 22 (no disability).
Query!
Timepoint [36]
0
0
Baseline; Through Week 48
Query!
Secondary outcome [37]
0
0
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [37]
0
0
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Query!
Timepoint [37]
0
0
Up to Week 48
Query!
Secondary outcome [38]
0
0
Number of Participants with Treatment-emergent Serious Adverse Events (TESAEs)
Query!
Assessment method [38]
0
0
An serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. TESAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.
Query!
Timepoint [38]
0
0
Up to Week 48
Query!
Eligibility
Key inclusion criteria
- Must have a diagnosis of Crohn's disease with a minimum duration of at least 3 months
- Has at least one active draining perianal fistula as a complication of Crohn's
disease, confirmed by screening magnetic resonance imaging (MRI) results
- Is naïve to biologics, or demonstrated inadequate response or intolerance to
conventional therapies or approved biologic therapies for Crohn's Disease (CD)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has a very severe luminal disease activity
- History of or concurrent rectovaginal fistulas, rectal and/or anal stenosis or other
active complications of perianal disease
- Has complications of CD, such as symptomatic strictures or stenoses, short gut
syndrome, or any other manifestation that might be anticipated to require surgery or
preclude fistula evaluation
- Any medical contraindications preventing study participation
- Has a history of ongoing, chronic or recurrent enteral or systemic infectious disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/09/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
17/05/2027
Query!
Actual
Query!
Sample size
Target
280
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Flinders Medical Centre - Adelaide
Query!
Recruitment hospital [2]
0
0
St Vincent's Hospital - Melbourne - Fitzroy
Query!
Recruitment hospital [3]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [4]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment hospital [5]
0
0
Royal Prince Alfred Hospital - Newtown
Query!
Recruitment hospital [6]
0
0
Royal Adelaide Hospital - North Terrace
Query!
Recruitment hospital [7]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [8]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment hospital [9]
0
0
Mater Hospital - South Brisbane
Query!
Recruitment postcode(s) [1]
0
0
5042 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [4]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [5]
0
0
2042 - Newtown
Query!
Recruitment postcode(s) [6]
0
0
5000 - North Terrace
Query!
Recruitment postcode(s) [7]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [8]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [9]
0
0
4101 - South Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Oklahoma
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Tennessee
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Bruxelles
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Leuven
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Liege
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Quebec
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Ceske Budejovice
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Praha 9
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Neuilly-sur-Seine
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Nice
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Pierre-Benite
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Rennes
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Vandoeuvre les Nancy
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Berlin
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Frankfurt
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Kiel
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Mannheim
Query!
Country [28]
0
0
Greece
Query!
State/province [28]
0
0
Athens
Query!
Country [29]
0
0
Greece
Query!
State/province [29]
0
0
Heraklion
Query!
Country [30]
0
0
Greece
Query!
State/province [30]
0
0
Patras
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Budapest
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Pecs
Query!
Country [33]
0
0
Israel
Query!
State/province [33]
0
0
Haifa
Query!
Country [34]
0
0
Israel
Query!
State/province [34]
0
0
Jerusalem
Query!
Country [35]
0
0
Israel
Query!
State/province [35]
0
0
Petah Tikva
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Milano
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Negrar ( Ve)
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Pisa
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
RHO
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
San Giovanni Rotondo
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Abiko
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Chikushino-shi
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Fukuoka-ken
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Fukuoka
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Hiroshima shi
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Hukuoka
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Kagoshima
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kashihara
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kashiwa
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Nagasaki
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Nagoya
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Nishinomiya
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Okayama
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Osaka
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Sakai
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Sapporo
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Shinjuku-ku
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Shizuoka
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Suita
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Tokyo
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Toyota
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Tsu
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Yokkaichi
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Yokohama
Query!
Country [65]
0
0
Jordan
Query!
State/province [65]
0
0
Amman
Query!
Country [66]
0
0
Jordan
Query!
State/province [66]
0
0
Irbid
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Busan
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Daegu
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Gyeonggi-do
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Seoul
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Amsterdam
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Nijmegen
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Utrecht
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Bialystok
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Krakow
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Lodz
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Rzeszow
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Szczecin
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Torun
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Warszawa
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Wroclaw
Query!
Country [82]
0
0
Portugal
Query!
State/province [82]
0
0
Braga
Query!
Country [83]
0
0
Portugal
Query!
State/province [83]
0
0
Lisboa
Query!
Country [84]
0
0
Portugal
Query!
State/province [84]
0
0
Porto
Query!
Country [85]
0
0
Saudi Arabia
Query!
State/province [85]
0
0
Dammam
Query!
Country [86]
0
0
Saudi Arabia
Query!
State/province [86]
0
0
Jeddah
Query!
Country [87]
0
0
Saudi Arabia
Query!
State/province [87]
0
0
Riyadh
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Barcelona
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Ferrol
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Madrid
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Majadahonda
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Sevilla
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Vigo
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Zaragoza
Query!
Country [95]
0
0
Taiwan
Query!
State/province [95]
0
0
Changhua
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taichung
Query!
Country [97]
0
0
Taiwan
Query!
State/province [97]
0
0
Taipei City
Query!
Country [98]
0
0
Taiwan
Query!
State/province [98]
0
0
Taoyuan City
Query!
Country [99]
0
0
Turkey
Query!
State/province [99]
0
0
Ankara
Query!
Country [100]
0
0
Turkey
Query!
State/province [100]
0
0
Istanbul
Query!
Country [101]
0
0
Turkey
Query!
State/province [101]
0
0
Izmir
Query!
Country [102]
0
0
Turkey
Query!
State/province [102]
0
0
Mersin
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Hull
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
London
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Newcastle Upon Tyne
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen-Cilag Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing,
perianal Crohn's disease and to assess the overall safety of guselkumab.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05347095
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen-Cilag Ltd. Clinical Trial
Query!
Address
0
0
Janssen-Cilag Ltd.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-434-4210
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05347095
Download to PDF